Aprea Therapeutics, Inc. (APRE) Financials

APRE Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 48.1 million 5.3 million
Dec. 31, 2025 15.9 million 3.5 million
Sept. 30, 2025 14.3 million 2.7 million
June 30, 2025 17.3 million 3.9 million

APRE Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -2.8 million 101068
Dec. 31, 2025 -3.1 million 109024
Sept. 30, 2025 -3.3 million 113754
June 30, 2025 -3.1 million 136729

APRE Net Income

No data available :(

APRE Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 46.5 million - -
Dec. 31, 2025 14.6 million - -
Sept. 30, 2025 13.7 million - -
June 30, 2025 16.5 million - -

APRE Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 7.7 million
Dec. 31, 2025 7.7 million
Sept. 30, 2025 6.4 million
June 30, 2025 6.1 million

APRE Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 1.6 million 1.8 million -
Dec. 31, 2025 - 1.0 million 1.6 million -
Sept. 30, 2025 1 1.6 million 1.5 million -
June 30, 2025 - 1.9 million 1.6 million -

APRE Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 5428
Dec. 31, 2025 3337 -4.4 million
Sept. 30, 2025 1848 5429
June 30, 2025 118111 1.9 million

APRE

Price: $0.63

52 week price:
0.55
2.22

Earnings Per Share: -1.49 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 118567

Market Capitalization: 4.8 million

Links: